IsoRay, Inc. (NYSEAMERICAN:ISR) shares saw unusually-strong trading volume on Tuesday . Approximately 1,279,800 shares changed hands during mid-day trading, an increase of 586% from the previous session’s volume of 186,685 shares.The stock last traded at $0.43 and had previously closed at $0.40.

Several equities analysts have issued reports on ISR shares. Maxim Group cut shares of IsoRay from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Zacks Investment Research cut shares of IsoRay from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. Finally, HC Wainwright set a $1.00 price objective on shares of IsoRay and gave the company a “hold” rating in a research note on Tuesday, November 13th.

IsoRay (NYSEAMERICAN:ISR) last announced its quarterly earnings data on Thursday, November 8th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $1.73 million.

In related news, CEO Lori A. Woods purchased 130,000 shares of the stock in a transaction dated Thursday, November 15th. The shares were acquired at an average cost of $0.40 per share, with a total value of $52,000.00. Following the purchase, the chief executive officer now directly owns 125,000 shares in the company, valued at approximately $50,000. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders acquired a total of 201,735 shares of company stock worth $81,619 over the last three months.

A hedge fund recently raised its stake in IsoRay stock. Vanguard Group Inc. increased its holdings in IsoRay, Inc. (NYSEAMERICAN:ISR) by 24.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,857,268 shares of the healthcare company’s stock after buying an additional 367,324 shares during the period. Vanguard Group Inc. owned about 2.76% of IsoRay worth $964,000 as of its most recent SEC filing.

TRADEMARK VIOLATION WARNING: “IsoRay (ISR) Sees Unusually-High Trading Volume” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at


IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Featured Article: QQQ ETF

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.